63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” 39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
2 citations
,
January 2024 in “SAGE Open Medical Case Reports” Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.
1 citations
,
October 2024 in “Journal of the Endocrine Society” Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
July 2025 in “Journal of Investigative Dermatology” High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
March 2005 in “The Nurse Practitioner” April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
49 citations
,
December 2018 in “JAAD case reports” Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
3 citations
,
September 2023 in “Advanced science” A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.
2 citations
,
January 2025 in “Journal of Oncology Pharmacy Practice” Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
July 2024 in “Journal of Investigative Dermatology” June 2025 in “British Journal of Dermatology” Dupilumab can cause psoriasis in some patients.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
2 citations
,
November 2024 in “JAAD Case Reports” 5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
April 2023 in “Journal of Investigative Dermatology” Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”